SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

Mankind Pharma

BSE: 543904 01 Jun 2025
Healthcare
₹ 2463
Mankind Pharma Limited specializes in Pharmaceuticals within the Healthcare sector.

Mankind Pharma - Share Price & Details

Market Cap
₹1,01,812
High /Low
3,055 / 1,901
Stock P/E
51.2
Book Value
₹347.0
Dividend Yield
0.0
ROCE
17.9
ROE
₹16.8
Face Value
1.0
PEG Ratio
3.47
EVEBITDA
₹30.8
Debt
8,511
CMP / FCF
65.6
Debt to equity
₹0.59
NP Ann
2,011
High price all time
3,055
Piotroski score
₹4.0
Graham Number
614.0
No. Eq. Shares
41.3
Net CF
₹-37.0
Net profit
2,011
Price to book value
7.1
Interest Coverage
₹6.86
Low price all time
1,241
Industry PE
32.7
Reserves
₹14,291
Free Cash Flow
₹1,895

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and ServicNANANANA4.6330.9
Triochem Products Ltd.,NANANANA0
Mankind Pharma Limited23459.13824.621265.99.251,01,81251.2
APOLLO HOSPITALS ENTERPRISE LTNANANANA9893168.4
Zydus Lifesciences Limited60050.028137.058196.027.969358020.1

Peer Comparison Chart


About Mankind Pharma

Mankind Pharma Limited, with Security Code 543904, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Mankind to expand gastro, derma presence, says MD Rajeev Juneja | Company Business News

(28 May 2025)
The pharmaceutical company is evaluating all options to increase its presence in therapy areas, including in-licensing products from...
Read more →

The Mankind Pharma Limited (NSE:MANKIND) Full-Year Results Are Out And Analysts Have Published New Forecasts

(24 May 2025)
Last week, you might have seen that Mankind Pharma Limited ( NSE:MANKIND ) released its full-year result to the market...
Read more →

Mankind Pharma eyes 26% FY26 growth as chronic therapies, OTC drive momentum

(23 May 2025)
Mankind's domestic business crossed ₹10000 crore in FY25, and the company is targeting 26% growth in FY26. Chronic therapies, which now make...
Read more →

Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr

(22 May 2025)
Mankind Pharma Limited has reported consolidated financial results for the period ended March 31, 2025. Mankind Pharma has posted net profit...
Read more →

Top Nifty Midcap Losers: Colgate, BSE Ltd, Mankind Pharma, Emami, Dixon Technologies stocks fall up to 5% today

(22 May 2025)
The NIFTY MIDCAP 150 index reflects the performance of these and other mid-sized companies, providing a broad view of this market segment.
Read more →

Mankind Pharma Q4 Results: Profit drops, revenue surges 27% on-year

(22 May 2025)
Mankind Pharma's Q4 profit declined 10.7% even as revenue grew 27% YoY. Management cited BSV integration, chronic therapy growth and exports...
Read more →